The news of Mizuho analyst Vamil Divan reiterating a Buy rating on Relmada Therapeutics and maintaining a $26 price target is positive for the stock. This reaffirms the analyst's confidence in the company's potential and could lead to increased investor interest, potentially driving the stock price up in the short term.